When patients with autoimmune diseases, such as rheumatoid arthritis (RA), are treated with potent immunosuppressive therapy, the risk of opportunistic diseases inevitably increases. If patients have the misfortune to suffer from both opportunistic and active autoimmune diseases, correct diagnosis could sometimes be difficult since both diseases have inflammatory nature. The choice of treatment is another challenge in that aggressive immunosuppressive therapy can fuel the opportunistic infection. Here we report a case of RA patient with new onset rheumatoid vasculitis that was diagnosed in the process of treatment of Pneumocystis jirovecii pneumonia.
Introduction
Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology. RA mainly affects the joint synovial membranes, but is a systemic disease in itself as well.
Rheumatoid vasculitis (RV) is among such systemic presentations of the disease. RV most commonly occurs in patients with longstanding and destructive RA and is sometimes even life-threatening. Here, we describe a case of a new-onset RV, the diagnosis of which was made difficult by the co-existence of Pneumocystis jirovecii pneumonia (PCP).
Case report
A 71-year-old man was admitted to Saitama Medical University Hospital. Approximately 15 years prior he had been diagnosed with RA. Since then, he had been prescribed a variety of disease-modifying anti-rheumaticdrugs (DMARDs), including bucillamine (BUC), leflunomide and actarit over a period of 13 years. However, the efficacy of the treatment proved insufficient and the level of serum C-reactive protein (CRP) continued to be more than 2.0 mg/dL during this time period. Two years before this admission, methotrexate (MTX: 6 mg/week) and etanercept (ETN: 25 mg/week) were started. Those drugs proved effective and the CRP level decreased to less than 0.5 mg/dL. He had been doing well until five months previously, when he had begun to feel fatigued, without any joint pain. Three months before the admission, the CRP level increased to 2.0 mg/dL and the dose of ETN was increased from 25 to 50 mg/week, without much improvement. The CRP level reached 9.0 mg/dL and abatacept (ABT) was started in place of ETN. Ten days later, 21 days before the admission, MTX was switched to BUC and oral prednisolone (PSL: 5 mg/day). Two days before this admission, fever, severe dyspnea and cough developed. The next day, he visited his physician. A chest X-ray revealed diffuse consolidation in the middle parts of the bilateral lungs. The patient was referred and admitted to this hospital. The disease activity of RA was moderate with disease activity score 28 based on ESR (DAS28-ESR) was 4.0 2) .
Thoracic computed tomography revealed bilateral diffuse ground-glass opacity ( Fig. 2A ) and fibrotic cysts (honeycomb changes) in the bilateral lower lobes (Fig. 2B) .
He was diagnosed with PCP. On the first hospital Although TMP-SMX was terminated due to side effects (rash, hyperkalemia and hyponatremia) on the 14th day, the treatment seemed effective. On the fifth day, Chest X-ray revealed improvement of the consolidation. On the seventh day, the CRP level decreased to 1.01 mg/dL. On the 11th day, the level of β-D-glucan came within the normal range (< 6.0 pg/mL). PSL was tapered slowly after the 21st day. Although the level of β-D-glucan remained below the detection limit, the CRP level rebounded and exceeded 8 mg/dL (Fig. 3) and, accordingly, the disease activity became high (DAS28-ESR: 6.3) on the 23rd day. We suspected the exacerbation of RA, so we added salazosulfapyridine (SASP: 500 mg/day) on the 29th day, which was increased to 1000 mg/day on the 44th day. Nevertheless, the CRP level did not decrease. On the 41st day, he developed ulcers on his heels. On the 48th day, the level of CH50 decreased to 16.1 IU/mL and that of IC-C1q was 4.0 µg/mL.
Skin biopsy of the ulcer lesion was performed and the specimen revealed small vessel vasculitis with fibrinoid necrosis (Fig. 4A-B) . Thus, we diagnosed him as having RV. Cardiac ultrasonography and nerve conduction velocity test were normal. He had neither episcleritis nor iritis. We increased PSL from 14 to 30 mg/day on the 56th day, followed by administration of tacrolimus (TAC:
3 mg/day) on the 67th day. The CRP level gradually decreased. On the 73rd day, the levels of CRP, CH50 and IC-C1q were 0.84 mg/dL, 28.4 IU/mL and 4.0 µg/mL, respectively. The ulcers were getting smaller. On the 85th day, the dose of PSL was tapered to 25 mg/day. The CRP level remained between 0.5 and 2.0 mg/dL and never came within normal range. We administrated ABT (500 mg) in place of TAC on the 88th day. PSL was tapered to 20 mg/day on the 99th day, followed by a second administration of ABT (500 mg) on the 101st day. Although the CRP level remained positive, his general condition had improved. On the 103rd day, he was discharged and continued to be treated at the clinic of this hospital. We tried to taper the dose of PSL, but the CRP level gradually increased and reached 11.1 mg/dL while that of CH50 remained as low as ~30 IU/mL. Thus, we gave up using ABT and SASP, increased the dose of PSL from 12 to 20 The final subject concerns the treatment of this patient.
Intensive immunosuppression is generally required for the treatment of RV, but the patient had just undergone PCP and was considered to be immunocompromised.
The ground-glass opacity almost disappeared, however, the fibrotic change remained. In addition, we had to cease using TMP-SMX due to side effects. Thus, the presence of remaining bacteria was our concern. As the level of β-D-glucan came within the normal range, we judged that we could intensify immunosuppressive therapy, although with great caution. Thus, we began treatment by moderately increasing the glucocorticoid dose (PSL, from 14 mg to 30 mg) and administering TAC. The skin ulcer became smaller but the CRP level did not normalize, so we replaced TAC with ABT. ABT was reported to be effective in a patient with refractory RV 7) and has been reported to be relatively safe for RA patients with a risk of infection 8) . Unfortunately, ABT did not diminish the inflammatory response, and we replaced ABT with AZA, which is often used for maintenance therapy after the induction of remission 9) . Since then, the inflammation of the patient has been under control and the dose of PSL has been tapered gradually.
To the best of our knowledge, this is the first report of new-onset RV during treatment of PCP. The infectious comorbidity complicated the diagnosis as well as the treatment of RV. Accumulation of similar cases would be of great help in establishing more effective and safer treatments for this dangerous condition.
